Cyclacel Pharmaceuticals (CYCC) - צמיחת רווחי EPS רבעונית
Cyclacel Pharmaceuticals focuses on developing small molecules for the selective destruction of solid tumors. In the long term, Cyclacel Pharmaceuticals relies on its expertise in CDK proteins and the drug fadraciclib. Quarterly EPS fluctuations on GURU.Markets reflect the current trend, where the indicator value is 99.40. The development strategy is based on the verification of early tests and the attraction of global partners in the general oncotherapy sector.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_CYCC_-_Cyclacel-Pharmaceuticals_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Cyclacel Pharmaceuticals Inc. (CYCC): לתקופה 04.07.2022 - 12.09.2025 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Cyclacel Pharmaceuticals
Investors assess the margin of safety through net earnings per share dynamics, which measure the rate of change in real quarterly income relative to the previous period. For Cyclacel Pharmaceuticals (CYCC), which depends on clinical trial outcomes and external financing, the quarterly EPS chart reveals critical volatility in fundamental metrics, confirming the asset's status as a high-speculative risk.
